J&J CFO Says 3Q Earnings Beat Driven by Actelion Deal

The transcript discusses a company's strong financial performance, driven by a 10% increase in sales and a 13% rise in earnings, surpassing market expectations. Key growth factors include recent acquisitions, such as Actelion, and robust performance in the pharmaceutical sector, particularly in immunology and oncology. The medical devices segment, bolstered by the acquisition of Abbott Medical Optics, shows stable growth despite weather-related disruptions. The company is also reviewing its diabetes device business, considering strategic options for its future.

What was the percentage increase in sales reported by the company for the quarter?

• 10%

• 20%

• 5%

• 15%

Which recent acquisition was highlighted as a major contributor to the company's growth?

• Pfizer

• Abbott Medical Optics

• Actelion

• Johnson & Johnson

How much was the Actelion acquisition worth?

• $40 billion

• $10 billion

• $20 billion

• $30 billion

What was the reported growth rate for the medical devices sector excluding acquisitions?

• 3.0%

• 0.5%

• 1.2%

• 2.5%

What strategic decision is the company considering for its diabetes device business?

• Entertaining offers for divestment

• Merging with another company

• Discontinuing all operations

• Expanding the product line